Development of an Electrophysiological Assay for Kv7 Modulators on IonWorks Barracuda

Assay Drug Dev Technol. 2019 Oct;17(7):310-321. doi: 10.1089/adt.2019.942.

Abstract

Relief from chronic pain continues to represent a large unmet need. The voltage-gated potassium channel Kv7.2/7.3, also known as KCNQ2/3, is a key contributor to the control of resting membrane potential and excitability in nociceptive neurons and represents a promising target for potential therapeutics. In this study, we present a medium throughput electrophysiological assay for the identification and characterization of modulators of Kv7.2/7.3 channels, using the IonWorks Barracuda™ automated voltage clamp platform. The assay combines a family of voltage steps used to construct conductance curves with a unique analysis method. Kv7.2/7.3 modulators shift the activation voltage and/or change the maximal conductance of the current, and both parameters have been used to quantify compound mediated effects. Both effects are expected to modulate neuronal excitability in vivo. The analysis method described assigns a single potency value that combines changes in activation voltage and maximal conductance and is expected to predict compound mediated changes in excitability.

Keywords: IonWorks Barracuda; KCNQ; Kv7; automated electrophysiology.

MeSH terms

  • Aminopyridines / analysis*
  • Aminopyridines / pharmacology
  • Carbamates / analysis*
  • Carbamates / pharmacology
  • Cells, Cultured
  • Drug Development*
  • Electrophysiological Phenomena
  • HEK293 Cells
  • High-Throughput Screening Assays / instrumentation*
  • Humans
  • KCNQ2 Potassium Channel / metabolism
  • KCNQ3 Potassium Channel / metabolism
  • Patch-Clamp Techniques / instrumentation*
  • Phenylenediamines / analysis*
  • Phenylenediamines / pharmacology

Substances

  • Aminopyridines
  • Carbamates
  • KCNQ2 Potassium Channel
  • KCNQ3 Potassium Channel
  • Phenylenediamines
  • ezogabine
  • flupirtine